THRB and Hepatic fibrosis: Resmetirom, a liver-targeted THR-β agonist, has been demonstrated to effectively reduce hepatic fat accumulation, ameliorate liver dysfunction, and improve liver fibrosis [12], while also exhibiting favorable safety and tolerability in clinical trials (Keam, 2024; Guirguis et al., 2025).